Cargando…
Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre
SIMPLE SUMMARY: The effectiveness and safety of immune checkpoint inhibitors in the treatment of patients with advanced cutaneous squamous cell carcinoma were evaluated in a real-world population, including patients who would have typically been excluded from clinical trials. We identified 36 patien...
Autores principales: | Koch Hein, Erica C., Vilbert, Maysa, Hirsch, Ian, Fernando Ribeiro, Mauricio, Muniz, Thiago P., Fournier, Cynthia, Abdulalem, Khaled, Saldanha, Erick F., Martinez, Erika, Spreafico, Anna, Hogg, David H., Butler, Marcus O., Saibil, Samuel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487051/ https://www.ncbi.nlm.nih.gov/pubmed/37686588 http://dx.doi.org/10.3390/cancers15174312 |
Ejemplares similares
-
Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy
por: Vilbert, Maysa, et al.
Publicado: (2023) -
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
por: Muniz, Thiago P., et al.
Publicado: (2021) -
Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature
por: Fournier, Cynthia, et al.
Publicado: (2023) -
Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
por: Priantti, Jonathan N., et al.
Publicado: (2023) -
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)